FAILSAFE
FAILSAFE

FAILSAFE Fungal Antimicrobial Resistance Innovations for Low & Middle Income Countries: Solutions & Access For Everyone

Criteria

 

GAMRIF core values

  • Developing innovative One Health solutions to tackle AFR
  • Increasing availability of context-specific, accessible and affordable innovations for LMICs
  • Establishing international research partnerships with industry, academia and governments
  • Collaborating with and leveraging additional funding from other global donors

ODA strategic objectives

  • Strengthening global peace, security and governance
  • Strengthening resilience and response to crises
  • Promoting global prosperity
  • Tackling extreme poverty and helping the world’s most vulnerable

FAILSAFE funding priorities

  • Research that will deliver outputs/outcomes that are primarily of benefit to LMICs
  • Tangible solutions/product development tackling the global challenge of AFR
  • Generation of novel partnerships (e.g. between LMIC and HIC partners, or between LMIC partners) including with industry
  • LMIC involvement
  • Industry engagement
  • Clear pathway to attract follow-on funding and impact
  • Research governance in place (e.g. collaboration agreements/IP considerations)
  • Targeting pre-clinical & clinical transitional bottlenecks

FAILSAFE research themes

Microbial Pathogenesis: This theme focusses on host-pathogen interactions as drivers of pathogen and immune adaptation, including co-infection and the impact of therapeutic or prophylactic interventions; and analyses of immunological basis of host protection or susceptibility in humans and animals. This includes work on understanding and overcoming pathogen antimicrobial resistance mechanisms. The focus of the work performed under this theme should be on product and solution development, with the aim of developing new preventative (e.g. vaccines) and therapeutic approaches (including combination therapies, immunotherapies) to combat antifungal drug resistance. This research must target pre-clinical and clinical transitional bottlenecks that will meaningfully assist in the development of such approaches.

Biomarkers and Diagnostics: This theme focuses on identifying new biomarkers for fungal infections, including new diagnostic tools that will improve diagnosis and/or the targeted management of fungal infections, as well as identifying biomarkers to monitor the host response to therapy (prognostic biomarkers)

Innovative platforms: There is a paucity of data and evidence on fungal infections and AFR. This theme involves the creation of innovative platforms and systems, including AI, that enable the integration of both clinical data (including antifungal use) and laboratory data (including antifungal susceptibility) from different medical centres throughout LMICs. It is envisaged that such system innovations would help optimize diagnostic tools to identify the causative fungus, as well as its susceptibility pattern, and help create connectivity between, regional, national and international databases.

One Health: This theme is aimed at developing products or solutions to improve health against fungal infections in LIMCs through the creation of interdisciplinary R&D networks. This includes work that focuses on the interconnections among animal health, environmental and climatic changes as factors contributing to human infection. This also includes the development of products or solutions that enable monitoring or prevention of zoonotic transmission of fungi to human hosts and of understanding environmental conditions that may impact antifungal drug resistance. The impact of climate change of fungal pathogenicity and human health is of particular interest in this theme. Other tangible outputs from this theme could include the development of new policy as well as publications that document new theories of change (position pieces) and best practice etc.